UBS Group’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.48M Sell
239,456
-385,144
-62% -$3.2M ﹤0.01% 5239
2025
Q4
$6.51M Sell
624,600
-110,570
-15% -$1.11M ﹤0.01% 3755
2025
Q3
$6.61M Buy
735,170
+475,395
+183% +$4.17M ﹤0.01% 3746
2025
Q2
$3.38M Buy
259,775
+178,350
+219% +$2.68M ﹤0.01% 4279
2025
Q1
$2.06M Sell
81,425
-133,621
-62% -$3.97M ﹤0.01% 4681
2024
Q4
$7.39M Buy
215,046
+190,885
+790% +$8.61M ﹤0.01% 3399
2024
Q3
$1.19M Buy
24,161
+5,796
+32% +$297K ﹤0.01% 4501
2024
Q2
$1.11M Sell
18,365
-13,599
-43% -$777K ﹤0.01% 4331
2024
Q1
$1.65M Sell
31,964
-2,693
-8% -$132K ﹤0.01% 4131
2023
Q4
$1.4M Buy
34,657
+16,434
+90% +$482K ﹤0.01% 4187
2023
Q3
$508K Sell
18,223
-729
-4% -$21.7K ﹤0.01% 4642
2023
Q2
$546K Buy
18,952
+11,301
+148% +$251K ﹤0.01% 4745
2023
Q1
$128K Buy
7,651
+2,263
+42% +$32K ﹤0.01% 5731
2022
Q4
$68.3K Buy
5,388
+4,339
+414% +$52.8K ﹤0.01% 6469
2022
Q3
$13K Buy
+1,049
New +$14.4K ﹤0.01% 8062
2022
Q2
Sell
-3,888
Closed -$48K 10848
2022
Q1
$48K Buy
3,888
+282
+8% +$3.39K ﹤0.01% 6540
2021
Q4
$40K Buy
+3,606
New +$43.3K ﹤0.01% 7124

Other funds holding RXST

UBS Group's RXST Position: Q1 2026 in Review

UBS Group reduced its RxSight (RXST) stake by 62% in Q1 2026, selling an estimated $3.2M and leaving 239,456 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #5239.

UBS Group first reported a position in RXST in Q4 2021 and has held it in 17 quarters since. The position peaked at $7.39M in Q4 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • UBS Group held 239,456 shares of RxSight worth $1.48M as of Q1 2026.
  • UBS Group sold 385,144 RxSight shares in Q1 2026, an estimated $3.2M.
  • RxSight made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5239 holding.
  • UBS Group first reported a position in RxSight in Q4 2021 and has held it in 17 quarters since.
  • UBS Group's RxSight position peaked at $7.39M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.